CN1340341A - Thiaminogen injection and its preparing process - Google Patents
Thiaminogen injection and its preparing process Download PDFInfo
- Publication number
- CN1340341A CN1340341A CN 00122929 CN00122929A CN1340341A CN 1340341 A CN1340341 A CN 1340341A CN 00122929 CN00122929 CN 00122929 CN 00122929 A CN00122929 A CN 00122929A CN 1340341 A CN1340341 A CN 1340341A
- Authority
- CN
- China
- Prior art keywords
- oryzanol
- oil
- injection
- production technology
- thiaminogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A thiaminogen injection for treating headache syndrome, vegetative neuve disfunction, climacteric syndrome, pregnancy vomiting, etc. is prepared through treating vegetable oil by neutral free fatty acid, decolouring, deodouring, sterilizing molecular cutting and magnetizing oil in a magnetic field with 100-1000 mTex for 2-10 hr, proportionally dissolving the refined thiaminogen in the oil at 80-120 deg.C, cooling them filtering, sterializing and bottling.
Description
The invention discloses a kind of oryzanol injection and production technology, relate to the biochemistry pharmacy
Technical field.
Oryzanol is the medicine of extensive application clinically, and the oryzanol preparation of using is oral tablet and oral liquid basically at present, and The experimental results shows that oral formulations is difficult for being absorbed by the body, and curative effect is not remarkable.Because oryzanol is insoluble in water, has run into very big difficulty when people are made into injection.Having only the YAMANOUCHI drugmaker of Japan to develop abroad can be for oryzanol preparation oral and injection, and it is the low concentration oryzanol aqueous solution of a kind of PVP of containing, also can add simultaneously several other surfactants with its stability of formulation.However, the stability of its injection or unsatisfactory is separated out solid particle when room temperature is placed easily, and the concentration of its preparation also has been subjected to very big restriction, can only make the low concentration preparation, and all these has influenced the application clinically of its injection.
The object of the present invention is to provide a kind of oryzanol injection and production technology, utilize a kind of suitable non-water-soluble matchmaker's method that the concentration of oryzanol preparation, stability are improved, thereby improve the degree of absorption of human body, reach better therapeutic it.
The objective of the invention is to realize by following technical scheme: the present invention with vegetable oil through in and free-fat acid treatment and decolouring and deodorizing, again behind dry heat sterilization, oil is placed 100-1000 milli tesla magnetic field effect 2-10 hour, carry out the molecule cutting, make the oil molecule magnetization, last be heated to 80-120 ℃ of dissolving with the ratio of refining oryzanol that reflux with petroleum ether in (ratio of weight and number): 900-930: 20-60, after the cooling after filtration, sterilization, fill.
Good effect of the present invention is to provide a kind of oryzanol injection, owing to used through refining and magnetized vegetable oil as solvent, has wherein improved the absorption of human body to it thereby oryzanol can be dissolved in higher concentration, has strengthened curative effect.Also improved simultaneously stability of formulation.Can be widely used in headache syndrome, autonomic nervous dysfunction, climacteric syndrome, vomiting during pregnancy, peripheral neuritis, the premenstruum strong disease and disease such as primary dysmenorrhea of incidence damage institute lemma.
Using method: intramuscular injection, dosage are 40mg/2ml days.
A: its stability of formulation is tested, and clarity and changes of contents situation are as follows when under 40 ℃ situation the variable concentrations sample being placed 0,30,60,90 day:
| Standing time (my god) | ????0 | ????30 | ????60 | ????90 |
| Clarity | Clear and bright | Clear and bright | Clear and bright | Clear and bright |
| Content (mg/ml) | ????20.6 | ????20.6 | ????20.1 | ????19.5 |
B. cause its syndrome model of artificial climacteric with the roentgen radiation x rat ovary, observe the therapeutical effect of oryzanol injection these rats.Dosage is 20mg/kg, establishes oryzanol water injection matched group (20mg/kg) simultaneously, oryzanol tablets matched group (20mg/kg), blank group and positive controls.Raise each treated animal after 20 days, get hypophysis, uterus, ovary and carry out pathology section examination, the result is as follows:
| Group | Hypophysis | The uterus | Ovary |
| The blank group | Alkali is had a liking for by each one of adenohypophysis and chromophobe cell is normal | Inner membrance, serous coat and epithelium, flesh skin are normal | Cortex, medullary substance, follicle at different levels and corpus luteum are normal |
| Positive controls | Adenopituicyte obviously increases, the alkalescence cytosis, visible hyperplastic nodule | The atrophy of inner membrance gland cell, it is empty that cell becomes, and a large amount of cell infiltration are arranged | Follicles at different levels and corpus luteum obviously reduce, and seldom see inflammatory cell |
| The oryzanol tablets matched group | Adenopituicyte increases, the alkalescence cytosis, visible a small amount of hyperplastic nodule | The intimal epithelium cell is arranged loose, cell volume is less, and inflammatory cell infiltration is arranged | Follicles at different levels and corpus luteum obviously reduce, and seldom see inflammatory cell |
| Oryzanol water injection matched group | Adenopituicyte slightly increases, the alkalescence cell slightly increases, and a small amount of hyperplastic nodule is arranged | The intimal epithelium cell is arranged slightly loose, visible a small amount of cell infiltration | Follicles at different levels and corpus luteum obviously reduce, and seldom see inflammatory cell |
| Experimental group | Adenopituicyte is normal substantially, the alkalescence cell slightly increases no hyperplastic nodule | The intimal epithelium cell is normal substantially, and inflammatory cell obviously is less than matched group | Follicles at different levels and corpus luteum obviously reduce, and seldom see inflammatory cell |
The present invention is further illustrated below in conjunction with embodiment:
Embodiment 1
With soybean oil through in and free-fat acid treatment and decolouring and deodorizing, again behind dry heat sterilization, oil is placed 350 milli teslas magnetic field effect 4 hours, carry out the molecule cutting, make the oil molecule magnetization, be heated to 80 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether at last in 900g: 20g.
Embodiment 2
With Oleum Sesami through in and free-fat acid treatment and decolouring and deodorizing, again behind dry heat sterilization, oil is placed 350 milli teslas magnetic field effect 4 hours, carry out the molecule cutting, make the oil molecule magnetization, be heated to 100 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether at last in 915g: 35g.
Embodiment 3
With Oleum Arachidis hypogaeae semen through in and free-fat acid treatment and decolouring and deodorizing, again behind dry heat sterilization, oil is placed 350 milli teslas magnetic field effect 4 hours, carry out the molecule cutting, make the oil molecule magnetization, be heated to 120 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether at last in 930g: 40g.
Embodiment 4
With soybean oil through in and free-fat acid treatment and decolouring and deodorizing, again behind dry heat sterilization, oil is placed 350 milli teslas magnetic field effect 4 hours, carry out the molecule cutting, make the oil molecule magnetization, be heated to 90 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether at last in 930g: 30g (ratio of weight and number).
Embodiment 5
To carry out decolouring and deodorizing again with the free-fat acid treatment in the Oleum Sesami warp, make refined oil with operations such as dry heat sterilizations at last and be heated to 120 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether in 920g: 40g (ratio of weight and number).
Embodiment 6
To carry out decolouring and deodorizing again with the free-fat acid treatment in the Oleum Arachidis hypogaeae semen warp, make refined oil with operations such as dry heat sterilizations at last and be heated to 100 ℃ of dissolvings, cooled and filtered, sterilization, fill with the ratio of refining oryzanol that reflux with petroleum ether in 910g: 20g (ratio of weight and number).
Claims (4)
1, a kind of oryzanol injection and production technology may further comprise the steps: with vegetable oil through in and after the free-fat acid treatment, make the refined plant oil solvent through dry heat sterilization behind the decolouring and deodorizing again; The reuse petroleum ether refluxes refining oryzanol with (ratio of weight and number) 900-930: 20-40 mixed, and heating for dissolving, sterilization filling behind cold filtration.
2, a kind of oryzanol injection according to claim 1 and production technology is characterized in that described vegetable oil comprises soybean oil, Oleum Sesami, Oleum Arachidis hypogaeae semen.
3, a kind of oryzanol injection according to claim 1 and 2 and production technology is characterized in that oil being placed 100-1000 milli tesla magnetic field effect 2-10 hour behind the dry heat sterilization, cut, the magnetized oil molecule.
4, require a kind of oryzanol injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00122929 CN1340341A (en) | 2000-08-25 | 2000-08-25 | Thiaminogen injection and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00122929 CN1340341A (en) | 2000-08-25 | 2000-08-25 | Thiaminogen injection and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1340341A true CN1340341A (en) | 2002-03-20 |
Family
ID=4589421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00122929 Pending CN1340341A (en) | 2000-08-25 | 2000-08-25 | Thiaminogen injection and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1340341A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386082C (en) * | 2005-12-22 | 2008-05-07 | 济南百诺医药科技开发有限公司 | Oryzanol composition and its preparation method |
| CN101480402B (en) * | 2008-12-17 | 2012-05-23 | 北京世纪博康医药科技有限公司 | Cycloartenyl ferulate composition and method for preparing the same |
-
2000
- 2000-08-25 CN CN 00122929 patent/CN1340341A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386082C (en) * | 2005-12-22 | 2008-05-07 | 济南百诺医药科技开发有限公司 | Oryzanol composition and its preparation method |
| CN101480402B (en) * | 2008-12-17 | 2012-05-23 | 北京世纪博康医药科技有限公司 | Cycloartenyl ferulate composition and method for preparing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| CN101731665B (en) | Enzymolysis method for crocodile tissues and preparation method for crocodile wine | |
| CN1171610C (en) | Traditional Chinese medicine injection for curing cardiovascular and cerebrovascular diseases and fundus disease and its preparing method | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN106511512A (en) | Traditional Chinese medicine external-use gel and preparation method and application thereof | |
| CN101791285B (en) | Clausenamide composite nanometer emulsion for clearing facial age pigment (lipofuscin) and preparation method thereof | |
| CN103494746B (en) | The novelty teabag of Lignum Santali Albi and a kind of Chinese medicine compound sunscreen composition | |
| CN103007000A (en) | New medicine for treating burns and wounds and preparation method thereof | |
| CN108079074A (en) | Compound hydrochloric acid terbinafine emulsifiable paste and preparation method thereof | |
| CN1340341A (en) | Thiaminogen injection and its preparing process | |
| KR102270386B1 (en) | Composition for Bone Begeneration comprising Recombinant Adipose-Derived Stem Cell | |
| DE19961141A1 (en) | Pharmaceutical composition of spider venoms and their preparation and use for the treatment of tumor diseases | |
| CN104127473B (en) | A kind of pharmaceutical composition for treating bone disease and its injection and preparation method | |
| CN107375334B (en) | Placenta extract and its preparation method and application | |
| CN100408033C (en) | Fat emulsion of biobalide B and preparation method | |
| CN109674997A (en) | A kind of transdermal absorbing composition containing Herba Blumeae Balsamiferae extract | |
| CN105362140A (en) | Non-cosmetics preservative composition with anticorrosion effect and application of non-cosmetics preservative composition | |
| CN105456528A (en) | Suppository for treating gynecological inflammation and preparation method thereof | |
| CN102626427B (en) | Ginkgo dipyridamole composition and preparation method of preparation thereof | |
| CA2493277C (en) | Antipyrotic and method of manufacturing the same | |
| CN100457101C (en) | Propylgallate injection with favorable solubility and its preparation process | |
| CN101081256A (en) | Medicine having good function of treating eye disease | |
| CN105943606B (en) | A pharmaceutical composition for treating cerebral ischemia and preparation method thereof | |
| RU2769508C2 (en) | Method for producing combined preparation of animal placenta and phyto-raw material | |
| CN102247381A (en) | VitaminD2-and-vitaminE-containing medicinal composition for injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |